THRX Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PIRKIMAS 109065 min ago

@ $4.06

Išleistas: 12 vas. 2024 @ 23:00

Grąža: 0.12%

Live Chart Being Loaded With Signals

Commentary (13 vas. 2024 @ 22:59):

Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients...

Stats
Šios dienos apimtis	677 694
Vidutinė apimtis	849 600
Rinkos kapitalizacija	181.50M
EPS	$0 ( 2024-03-14 )
Kita pelno data	( $0 ) 2024-05-11
Last Dividend	$0.250 ( 2015-09-08 )
Next Dividend	$0 ( N/A )
P/E	-3.03
ATR14	$0.0670 (1.65%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-14	Yi Kathy	Sell	3 250	Restricted Stock Units
2024-02-14	Yi Kathy	Sell	99 634	Stock Option (Right to Buy)
2024-02-14	Stein Steven H	Sell	3 250	Restricted Stock Units
2024-02-14	Orbimed Advisors Llc	Sell	650 600	Common Stock
2024-02-14	Hayden Donald J Jr	Sell	10 000	Common Stock

INSIDER POWER
-12.55
Last 94 transactions
Buy: 24 821 782 \| Sell: 19 785 944

Tūris Koreliacija

Ilgas: 0.04 (neutral)

Trumpas: 0.00 (neutral)

Signal:(59.853) Neutral

Theseus Pharmaceuticals, Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
PXLW	0.931
ADXN	0.921
LIAN	0.92
TNXP	0.917
JFIN	0.914
DSKE	0.906
SPRB	0.904
SRRK	0.902
MEUSW	0.897
LX	0.895

10 Labiausiai neigiamai susiję koreliacijos
GRPH	-0.881
AHPI	-0.842
EA	-0.834
TUEM	-0.826
VERA	-0.818
MTEX	-0.814
LCAP	-0.812

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Theseus Pharmaceuticals, Koreliacija - Valiuta/Žaliavos

-0.87
( strong negative )

-0.91
( very strong negative )

0.00
( neutral )

-0.80
( moderate negative )

-0.20
( neutral )

0.95
( very strong )

Theseus Pharmaceuticals, Finansinės ataskaitos

Annual	2022
Pajamos:	$0
Bruto pelnas:	$-438 000 (0.00 %)
EPS:	$-1.220

FY	2022
Pajamos:	$0
Bruto pelnas:	$-438 000 (0.00 %)
EPS:	$-1.220

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-2.84

FY	2020
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-1.010

Financial Reports:

No articles found.

Theseus Pharmaceuticals, Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Theseus Pharmaceuticals, Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 0 - N/A | Divividend Growth Potential Score: 0 - N/A

Information

First Dividend	$0.250	2014-08-26
Last Dividend	$0.250	2015-09-08
Next Dividend	$0	N/A
Payout Date	2015-09-30
Next Payout Date	N/A
# dividends	5	--
Total Paid Out	$1.250	--
Avg. Dividend % Per Year	0.00%	--
Score	1.55	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-06-19)

$0 Estimate 0.00 %

Dividend Stability

0.03 Very Bad

Dividend Score

1.55

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
2014	$0	0.00%
2015	$0	0.00%
2016	$0	0.00%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

Unable to generate commentary due to missing data.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0	1.500	0	0	[0 - 0.5]
returnOnAssetsTTM	-0.238	1.200	-7.94	-9.52	[0 - 0.3]
returnOnEquityTTM	-0.245	1.500	-3.83	-5.75	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	29.93	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	29.29	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	6.70	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.0156	-1.500	9.74	-10.00	[0 - 0.6]
interestCoverageTTM	88.35	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	-1.133	2.00	-0.378	-0.755	[0 - 30]
freeCashFlowPerShareTTM	-1.134	2.00	-0.567	-1.134	[0 - 20]
debtEquityRatioTTM	0.0163	-1.500	9.93	-10.00	[0 - 2.5]
grossProfitMarginTTM	0	1.000	-3.33	-3.33	[0.2 - 0.8]
operatingProfitMarginTTM	0	1.000	-2.00	-2.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-13.58	1.000	-10.00	-10.00	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				1.984

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-3.19	1.000	-0.423	0	[1 - 100]
returnOnEquityTTM	-0.245	2.50	-2.46	-5.75	[0.1 - 1.5]
freeCashFlowPerShareTTM	-1.134	2.00	-0.378	-1.134	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-1.133	2.00	-0.378	-0.755	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.00632	1.500	-3.29	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0	1.000	-2.50	0	[0.1 - 0.5]
Total Score				-1.553

Theseus Pharmaceuticals,

Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also develops fourth-generation EGFR inhibitor that is active against C797S, an EGFR mutation that causes resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.